ticlopidine has been researched along with Arteriosclerosis in 111 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 9.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "The aim was to test within a randomized double-blind trial whether the platelet inhibitor ticlopidine might improve peripheral blood flow and distal pressures in patients with aortofemoral arteriosclerosis." | 9.07 | Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study. ( Fagher, B, 1994) |
| "Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent." | 9.05 | Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. ( Aukland, A; George, AJ; Hurlow, RA; Stuart, J, 1982) |
| " The drug is widely used in combination with aspirin for the prevention of atherothrombosis after placement of intravascular stents, and available data suggest that this combination is as effective as ticlopidine plus aspirin for this indication." | 8.80 | Clopidogrel: a review of its use in the prevention of atherothrombosis. ( Jarvis, B; Simpson, K, 2000) |
| "It was previously shown that the combination of clopidogrel and everolimus reduced the development of transplant arteriosclerosis." | 7.81 | Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. ( Eckl, S; Ensminger, SM; Goldmann, K; Heim, C; Koch, N; Preidl, R; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M, 2015) |
| "Our group has shown that platelet inhibition with clopidogrel, an antagonist of the P2Y12 adenosine diphosphate receptor on platelets, reduced the formation of transplant arteriosclerosis." | 7.76 | Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. ( Abele-Ohl, S; Eckl, S; Ensminger, SM; Heim, C; Hoffmann, J; Ramsperger-Gleixner, M; Weyand, M, 2010) |
| "Monotherapy with clopidogrel reduced the formation of transplant arteriosclerosis in a murine aortic allograft model." | 7.75 | Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. ( Abele, S; Ensminger, SM; Hiemann, NE; Nieswandt, B; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M; Wollin, M, 2009) |
| "When mice were treated daily with 1 mg/kg clopidogrel in the absence of any other immunosuppression, transplant arteriosclerosis was significantly reduced compared with that seen in saline-treated control animals (intimal proliferation of 66% +/- 9% [1 mg/kg clopidogrel] vs 77% +/- 5% [control], n = 7, P < or = ." | 7.73 | Clopidogrel reduces the development of transplant arteriosclerosis. ( Abele, S; Ensminger, SM; Fischlein, T; Harig, F; Hiemann, NE; Weyand, M; Wollin, M, 2006) |
| "This study determines the antiplatelet effects of oral ticlopidine (100 mg/kg x day) in experimental hypercholesterolemia." | 7.69 | Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. ( Braun, M; Hohlfeld, T; Scharnowski, F; Schrör, K, 1994) |
| "Ticlopidine is a new drug for the inhibition of the aggregation of platelets, which is used in arteriosclerosis." | 7.67 | [Thrombocytopenia due to antibodies induced by ticlopidine]. ( Claas, FH; de Fraiture, WH; Meyboom, RH, 1984) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "This large-scale trial of patients at high risk for atherothrombotic events will allow determination of the value of a strategy of adding clopidogrel to the current standard of care, including low-dose aspirin, for a wide spectrum of patients with atherothrombosis." | 5.11 | Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. ( Bhatt, DL; Topol, EJ, 2004) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 5.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "The aim was to test within a randomized double-blind trial whether the platelet inhibitor ticlopidine might improve peripheral blood flow and distal pressures in patients with aortofemoral arteriosclerosis." | 5.07 | Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study. ( Fagher, B, 1994) |
| "The influence of the platelet inhibitory drug Ticlopidine (T) (500 mg daily) on lipoprotein metabolism was investigated in a double-blind placebo-controlled study of 38 middle-aged men with incapacitating stable angina pectoris." | 5.06 | Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine. ( Berglund, U; Wallentin, L, 1986) |
| "Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent." | 5.05 | Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. ( Aukland, A; George, AJ; Hurlow, RA; Stuart, J, 1982) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| " The drug is widely used in combination with aspirin for the prevention of atherothrombosis after placement of intravascular stents, and available data suggest that this combination is as effective as ticlopidine plus aspirin for this indication." | 4.80 | Clopidogrel: a review of its use in the prevention of atherothrombosis. ( Jarvis, B; Simpson, K, 2000) |
| "It was previously shown that the combination of clopidogrel and everolimus reduced the development of transplant arteriosclerosis." | 3.81 | Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. ( Eckl, S; Ensminger, SM; Goldmann, K; Heim, C; Koch, N; Preidl, R; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M, 2015) |
| " These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis." | 3.79 | Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Creager, MA, 1998) |
| "Patients who have had a recent transient ischemic attack (TIA) are at high risk for subsequent stroke." | 3.77 | Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly. ( Adams, HP; Gordon, DL, 1991) |
| "Our group has shown that platelet inhibition with clopidogrel, an antagonist of the P2Y12 adenosine diphosphate receptor on platelets, reduced the formation of transplant arteriosclerosis." | 3.76 | Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. ( Abele-Ohl, S; Eckl, S; Ensminger, SM; Heim, C; Hoffmann, J; Ramsperger-Gleixner, M; Weyand, M, 2010) |
| "Monotherapy with clopidogrel reduced the formation of transplant arteriosclerosis in a murine aortic allograft model." | 3.75 | Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. ( Abele, S; Ensminger, SM; Hiemann, NE; Nieswandt, B; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M; Wollin, M, 2009) |
| "When mice were treated daily with 1 mg/kg clopidogrel in the absence of any other immunosuppression, transplant arteriosclerosis was significantly reduced compared with that seen in saline-treated control animals (intimal proliferation of 66% +/- 9% [1 mg/kg clopidogrel] vs 77% +/- 5% [control], n = 7, P < or = ." | 3.73 | Clopidogrel reduces the development of transplant arteriosclerosis. ( Abele, S; Ensminger, SM; Fischlein, T; Harig, F; Hiemann, NE; Weyand, M; Wollin, M, 2006) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "This study determines the antiplatelet effects of oral ticlopidine (100 mg/kg x day) in experimental hypercholesterolemia." | 3.69 | Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. ( Braun, M; Hohlfeld, T; Scharnowski, F; Schrör, K, 1994) |
| "The effect of several anti-atherogenic drugs (ticlopidine, nicotinic acid and etofibrate) on immune responses and immune complex anaphylaxis has been studied in mice." | 3.67 | Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes. ( Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM, 1985) |
| "Ticlopidine is a new drug for the inhibition of the aggregation of platelets, which is used in arteriosclerosis." | 3.67 | [Thrombocytopenia due to antibodies induced by ticlopidine]. ( Claas, FH; de Fraiture, WH; Meyboom, RH, 1984) |
| " Platelet aggregation induced by 5 microM of ADP was measured in plasma samples taken at screening, 2 hours after dosing on day 1 to day 9; 2, 5, and 24 hours after dosing on day 10; and on alternate days until day 24." | 2.69 | Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. ( Denninger, MH; Necciari, J; Serre-Lacroix, E; Sissmann, J, 1999) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction." | 2.68 | [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996) |
| " The clinical benefit of ticlopidine in PAD without adverse reactions can be confirmed at least at the dosage of 750 mg/d instead of the usual dose of 500 mg/d." | 2.66 | Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease. ( Battocchio, F; Crociani, ME; Fabris, F; Girolami, A; Randi, ML, 1985) |
| " These results demonstrated that long-term administration of clopidogrel was effective in preventing ischaemic events in patients with atherosclerotic vascular disease including PAD." | 2.41 | Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. ( Hiatt, WR, 2002) |
| "No or only a mild restenosis developed in 27 patients." | 1.32 | Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results. ( Butz, B; Feuerbach, S; Lenhart, M; Link, J; Paetzel, C; Pfister, K; Schleicher, T; Stern, U, 2004) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (23.42) | 18.7374 |
| 1990's | 34 (30.63) | 18.2507 |
| 2000's | 48 (43.24) | 29.6817 |
| 2010's | 3 (2.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heim, C | 2 |
| Eckl, S | 2 |
| Preidl, R | 1 |
| Ramsperger-Gleixner, M | 3 |
| Koch, N | 1 |
| Goldmann, K | 1 |
| Spriewald, BM | 2 |
| Weyand, M | 4 |
| Ensminger, SM | 4 |
| Müller-Ehmsen, J | 1 |
| Erdmann, E | 1 |
| Abele, S | 2 |
| Wollin, M | 2 |
| Hiemann, NE | 2 |
| Nieswandt, B | 1 |
| Abele-Ohl, S | 1 |
| Hoffmann, J | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Fettser, DV | 1 |
| Batyraliev, TA | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Brinkman, WT | 1 |
| Terramani, TT | 1 |
| Najibi, S | 1 |
| Chaikof, EL | 1 |
| Komarov, AL | 1 |
| Kropacheva, ES | 1 |
| Tarasova, TN | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Mironova, IY | 1 |
| Naumov, VG | 1 |
| Panchenko, EP | 1 |
| Lecompte, T | 1 |
| Cha, JK | 1 |
| Jeong, MH | 1 |
| Lee, KM | 1 |
| Bae, HR | 1 |
| Lim, YJ | 1 |
| Park, KW | 1 |
| Cheon, SM | 1 |
| Ziegler, BK | 1 |
| Rasmussen, LH | 1 |
| Kristensen, SD | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 1 |
| Ringleb, PA | 2 |
| Bhatt, DL | 2 |
| Hirsch, AT | 1 |
| Topol, EJ | 2 |
| Hacke, W | 1 |
| Diener, HC | 1 |
| Bogousslavsky, J | 3 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Csiba, L | 1 |
| Kaste, M | 1 |
| Leys, D | 1 |
| Matias-Guiu, J | 1 |
| Rupprecht, HJ | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Rodgers, JE | 1 |
| Steinhubl, SR | 1 |
| Jagroop, IA | 1 |
| Matsagas, MI | 1 |
| Geroulakos, G | 1 |
| Mikhailidis, DP | 1 |
| Schellinger, PD | 1 |
| Schwark, C | 1 |
| Jacobson, AK | 1 |
| Lewis, SC | 1 |
| Warlow, CP | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Butz, B | 1 |
| Paetzel, C | 1 |
| Stern, U | 1 |
| Schleicher, T | 1 |
| Pfister, K | 1 |
| Link, J | 1 |
| Feuerbach, S | 1 |
| Lenhart, M | 1 |
| Cavendish, JJ | 1 |
| Safani, M | 1 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Moussouttas, M | 1 |
| Savi, P | 1 |
| Herbert, JM | 1 |
| Kiss, RG | 1 |
| Zhao, L | 1 |
| Gray, L | 1 |
| Leonardi-Bee, J | 1 |
| Weaver, CS | 1 |
| Heptinstall, S | 1 |
| Bath, PM | 1 |
| Harig, F | 1 |
| Fischlein, T | 1 |
| Faxon, DP | 1 |
| Nesto, RW | 1 |
| Gaciong, Z | 1 |
| Toyoda, K | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Minematsu, K | 1 |
| Jamieson, DG | 1 |
| Murat, O | 1 |
| Durand, E | 1 |
| Delépine, G | 1 |
| Nguyen, P | 1 |
| Malinovsky, JM | 1 |
| Verstraete, M | 1 |
| Violi, F | 2 |
| Alessandri, C | 2 |
| Frattaroli, S | 1 |
| Ghiselli, A | 2 |
| Balsano, F | 2 |
| Numano, F | 1 |
| Lasierra, J | 3 |
| Díez, MM | 1 |
| Fernández, A | 2 |
| Viladés, E | 2 |
| Gil, M | 2 |
| Velázquez, E | 3 |
| Claas, FH | 1 |
| de Fraiture, WH | 1 |
| Meyboom, RH | 1 |
| Hawker, RJ | 1 |
| Aukland, A | 2 |
| Sánchez Casajús, A | 1 |
| Martínez Peñuela, JM | 1 |
| Lenci, R | 1 |
| Galante, A | 1 |
| Borzi, M | 1 |
| Ariganello, M | 1 |
| Sommariva, L | 1 |
| Filice, A | 1 |
| Cannata, D | 1 |
| Castaigne, A | 1 |
| Benghozi, R | 1 |
| Bienvenu, MP | 1 |
| Katsumura, T | 1 |
| Mishima, Y | 1 |
| Kamiya, K | 1 |
| Sakaguchi, S | 1 |
| Tanabe, T | 1 |
| Sakuma, A | 1 |
| Hurlow, RA | 1 |
| George, AJ | 1 |
| Stuart, J | 1 |
| Manotti, C | 1 |
| Potì, R | 1 |
| Megna, A | 1 |
| Poli, T | 1 |
| Alberani, M | 1 |
| Kirstein, P | 1 |
| Jogestrand, T | 1 |
| Johnsson, H | 1 |
| Olsson, AG | 1 |
| Hohlfeld, T | 2 |
| Scharnowski, F | 1 |
| Braun, M | 1 |
| Schrör, K | 2 |
| Pongratz, G | 1 |
| Pohle, K | 1 |
| Stingl, D | 1 |
| Bachmann, K | 1 |
| Kirichenko, AA | 1 |
| Prekina, VI | 1 |
| Repinskaia, NP | 1 |
| Novichkova, IuN | 1 |
| Ter-Gevondian, NM | 1 |
| Vinogradova, IV | 1 |
| Fagher, B | 1 |
| Castillo, V | 1 |
| Vuadens, P | 1 |
| Boneu, B | 1 |
| Destelle, G | 1 |
| Rosa, A | 1 |
| Canaple, S | 1 |
| Keil, Tu | 1 |
| Hankey, GJ | 1 |
| Becquemin, JP | 1 |
| Ferguson, JJ | 2 |
| Gonzalez, ER | 3 |
| Kannel, WB | 1 |
| Olin, JW | 1 |
| Raps, EC | 1 |
| Kannewurf, BS | 1 |
| Dormandy, JA | 1 |
| Creager, MA | 1 |
| Priollet, P | 1 |
| Feret, B | 1 |
| Denninger, MH | 1 |
| Necciari, J | 1 |
| Serre-Lacroix, E | 1 |
| Sissmann, J | 1 |
| Zusman, RM | 3 |
| Chesebro, JH | 1 |
| Comerota, A | 1 |
| Hartmann, JR | 1 |
| Massin, EK | 1 |
| Raps, E | 1 |
| Wolf, PA | 1 |
| Pfister, SM | 1 |
| Harker, LA | 2 |
| Boissel, JP | 2 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Wilson, JM | 1 |
| Ikeda, Y | 1 |
| van Kranen, RJ | 1 |
| Walvoort, HC | 1 |
| Einecke, D | 1 |
| Jarvis, B | 1 |
| Simpson, K | 1 |
| Montalescot, G | 1 |
| Bennett, JS | 1 |
| Scheen, AJ | 1 |
| Guile, SD | 1 |
| Ince, F | 1 |
| Ingall, AH | 1 |
| Kindon, ND | 1 |
| Meghani, P | 1 |
| Mortimore, MP | 1 |
| Ciuffetti, G | 1 |
| Lombardini, R | 1 |
| Pirro, M | 1 |
| Lupattelli, G | 1 |
| Mannarino, E | 1 |
| Shukla, V | 1 |
| Hiatt, WR | 1 |
| Uchiyama, S | 1 |
| Yamazaki, M | 1 |
| Iwata, M | 1 |
| Cohn, PF | 1 |
| Haynes, RB | 1 |
| Sandler, RS | 1 |
| Larson, EB | 1 |
| Pater, JL | 1 |
| Yatsu, FM | 1 |
| Randi, ML | 2 |
| Mares, M | 1 |
| Fabris, F | 2 |
| Tison, T | 1 |
| Barbone, E | 1 |
| Girolami, A | 2 |
| Adams, HP | 1 |
| Gordon, DL | 1 |
| Lièvre, M | 1 |
| Chirossel, P | 1 |
| Adenis, T | 1 |
| Amiel, M | 1 |
| Caimi, G | 1 |
| Lo Presti, R | 1 |
| Francavilla, G | 1 |
| Romano, A | 1 |
| Catalano, C | 1 |
| Santonocito, G | 1 |
| Sarno, A | 1 |
| Tesi, M | 1 |
| Bronchi, GF | 1 |
| Carini, A | 1 |
| Karavassili, M | 1 |
| Rojo, JM | 1 |
| Portolés, MP | 1 |
| Ojeda, G | 1 |
| Portolés, A | 1 |
| Berglund, U | 1 |
| Wallentin, L | 1 |
| Pellegreffi, L | 1 |
| Branzoli, U | 1 |
| Solvay, H | 1 |
| Kahn, M | 1 |
| Garreyn, S | 1 |
| Cloarec, M | 1 |
| Sneppe, R | 1 |
| Schram, E | 1 |
| Fenollar, JV | 1 |
| Nagakawa, Y | 1 |
| Matsushita, S | 1 |
| Di Perri, T | 1 |
| Díez, M | 1 |
| Iuliano, L | 1 |
| Perrone, A | 1 |
| Crociani, ME | 1 |
| Battocchio, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
34 reviews available for ticlopidine and Arteriosclerosis
| Article | Year |
|---|---|
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Blood Platelets; Clopidogrel; Endarter | 2002 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi | 2003 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
Platelet ADP receptor antagonists: ticlopidine and clopidogrel.
Topics: Arteriosclerosis; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antag | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 2005 |
[Mechanism and drug treatment of atherothrombosis].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; C-Reactive Protein; CD40 Antigens; Clopidogrel; Drug Ther | 2005 |
Antiplatelet therapy in populations at high risk of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Chemoprevention; Clopidogrel; Drug Therapy, Combination; Embolism, Choles | 2006 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocar | 1984 |
[Platelet activation and platelet aggregation in the arteriosclerotic endothelium: pathophysiological aspects and new therapeutic concepts].
Topics: Anticoagulants; Arteriosclerosis; Cyclooxygenase Inhibitors; Endothelium, Vascular; Humans; Platelet | 1995 |
[Preventive treatment of cerebrovascular accidents of arterial origin].
Topics: Adult; Aged; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials | 1996 |
Atherosclerosis: a unifying disorder with diverse manifestations.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; United | 1998 |
Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Activation; | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
[Arteriopathy of the lower limbs: toward a global medical care].
Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Cl | 1999 |
Clopidogrel: a new antiplatelet agent.
Topics: Arteriosclerosis; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 1999 |
Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Topics: Algorithms; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Critic | 1999 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
[Antiplatelet therapy].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clinic | 1999 |
Clopidogrel: a review of its use in the prevention of atherothrombosis.
Topics: Arteriosclerosis; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Humans; Platelet Activat | 2000 |
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggre | 2000 |
Novel platelet inhibitors.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Humans; Platelet A | 2001 |
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Purinergic P2 Receptor An | 2001 |
The medicinal chemistry of the P2 receptor family.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arterios | 2001 |
Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
Topics: Algorithms; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet A | 2002 |
[Prevention of recurrence in cerebral infarction].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebral Infarction; Drug Therapy, C | 2002 |
Role of antiplatelet agents in cardioprotection.
Topics: Arteriosclerosis; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Clopidogrel; Female; Humans; | 2002 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
28 trials available for ticlopidine and Arteriosclerosis
| Article | Year |
|---|---|
[Effect of therapy with clopidogrel on walking tolerance and parameters of hemostasis in patients with atherosclerosis of lower extremities and intermittent claudication].
Topics: Aged; Arteriosclerosis; Clopidogrel; Female; Hemostasis; Humans; Lower Extremity; Male; Middle Aged; | 2002 |
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D | 2002 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Dr | 2004 |
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
Effects of ticlopidine on platelet function and blood coagulation.
Topics: Adult; Aged; Arteriosclerosis; beta-Thromboglobulin; Blood Coagulation; Female; Fibrin Fibrinogen De | 1982 |
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1982 |
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
Topics: Adult; Aged; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent C | 1982 |
Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acids; Arteriosclerosis; Blood Coagulation; Epinephrine; Fe | 1980 |
Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study.
Topics: Adult; Aged; Arteriosclerosis; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent | 1994 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients.
Topics: Adult; Aged; Arteriosclerosis; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; | 1996 |
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re | 1996 |
[Recent antithrombotic gold standard?].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopi | 1997 |
Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Double-Blind Method; Female; Graft Occlusion, Vasc | 1997 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.
Topics: Adolescent; Adult; Age Factors; Aged; Arteriosclerosis; Bleeding Time; Clopidogrel; Humans; Male; Pl | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
[ASS or clopidogrel? In high vascular risk it is best to give both].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2000 |
Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis.
Topics: Adult; Arteriosclerosis; Blood Cell Count; Blood Viscosity; Clopidogrel; Double-Blind Method; Erythr | 2001 |
Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
Topics: Adult; Aged; Arteriosclerosis; Bleeding Time; Female; Fibrinogen; Humans; Male; Middle Aged; Platele | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Therapy of atherosclerotic arteriopathy of lower limbs. Aspects and results.
Topics: Acute Disease; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Glycosaminoglycans; Hepa | 1985 |
Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine.
Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Human | 1986 |
Blood lipid profile in healthy subjects treated with ticlopidine.
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Blood Platelets; Double-Blind Method; Drug Evaluation | 1985 |
Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease.
Topics: Aged; Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Viscosity; Female; Fibrinogen; Hum | 1985 |
52 other studies available for ticlopidine and Arteriosclerosis
| Article | Year |
|---|---|
Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts.
Topics: Allografts; Animals; Aorta; Arteriosclerosis; Clopidogrel; Disease Progression; Everolimus; Immunity | 2015 |
[Thrombocyte aggregation inhibitor after surgery for an abdominal aortic aneurysm].
Topics: Aortic Aneurysm, Abdominal; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Cardiov | 2008 |
Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Aorta, Abdominal; Arterios | 2009 |
Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Clopidogrel; Disease Models, Animal; Drug Therapy, Comb | 2010 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Pro | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2004 |
[Secondary prevention after ischemic stroke. High risk patients need special protection].
Topics: Arteriosclerosis; Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Humans; Intra | 2004 |
Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiography; Anticoagulants; Arterial Occlusive Disea | 2004 |
Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Clopidogrel; Female; Humans; Intermittent Claudication; M | 2004 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Emerging therapies: clopidogrel and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopid | 2005 |
[More modest use in secondary prevention, risky in primary prevention].
Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Bli | 2006 |
Clopidogrel reduces the development of transplant arteriosclerosis.
Topics: Animals; Aorta; Arteriosclerosis; Clopidogrel; Disease Models, Animal; Graft Rejection; Mice; Mice, | 2006 |
[Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study].
Topics: Aged; Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middl | 2006 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
Update on the use of antiplatelet agents in secondary stroke prevention.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, Cholester | 2007 |
[Spinal cord ischaemia and preoperative clopidogrel withdrawal in an arteriosclerotic patient].
Topics: Arteriosclerosis; Clopidogrel; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Spinal | 2008 |
[The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Aspirin; Fibrinolysis; Lysine; Male; Muscle, Smooth, Vascular; Rabbits; T | 1984 |
[Thrombocytopenia due to antibodies induced by ticlopidine].
Topics: Aged; Antibody Formation; Anticoagulants; Arteriosclerosis; Blood Platelets; Humans; Platelet Count; | 1984 |
Platelet survival, atherosclerotic intermittent claudication and ticlopidine.
Topics: Aged; Arteriosclerosis; Blood Platelets; Cell Survival; Humans; Indium; Intermittent Claudication; M | 1984 |
[Structural aspects of the kidney in experimental atheromatosis].
Topics: Animals; Arteriosclerosis; Blood Platelets; Fibrinolysis; Kidney; Male; Platelet Aggregation; Rabbit | 1984 |
[The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
Topics: Aged; Anticoagulants; Arteriosclerosis; Female; Humans; Male; Platelet Aggregation; Thiophenes; Ticl | 1983 |
[Platelet aggregation inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Dipyridamole; Humans; Platelet Aggregatio | 1981 |
Antiaggregant effect of ticlopidine in atherosclerotic patients.
Topics: Aged; Arteriosclerosis; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopi | 1982 |
Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia.
Topics: Adenosine Diphosphate; Animals; Aortic Diseases; Arteriosclerosis; Biotransformation; Cholesterol, D | 1994 |
[The efficacy of ticlid in treating intermittent claudication in atherosclerotic stenosis of the arteries of the lower extremities].
Topics: Adult; Arteriosclerosis; Blood Coagulation Tests; Hemostasis; Humans; Intermittent Claudication; Leg | 1994 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
Anticlotting drug approved.
Topics: Administration, Oral; Arteriosclerosis; Clopidogrel; Contraindications; Humans; Platelet Aggregation | 1998 |
Clopidogrel approved on basis of CAPRIE study.
Topics: Arteriosclerosis; Clopidogrel; Drug Approval; Humans; Platelet Aggregation Inhibitors; Ticlopidine; | 1998 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
Clopidogrel for reduction of atherosclerotic events.
Topics: Administration, Oral; Arteriosclerosis; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Hu | 1998 |
[Secondary cardiovascular prevention: convincing evidence concerning clopidogrel].
Topics: Arteriosclerosis; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 1998 |
Shifting paradigms of antiplatelet therapy: assessing new drugs versus old. Introduction.
Topics: Arteriosclerosis; Aspirin; Chemistry, Pharmaceutical; Clopidogrel; Humans; Platelet Aggregation Inhi | 1998 |
Rationale for antiplatelet therapy in patients with atherothrombotic disease.
Topics: Arteriosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Epopr | 1998 |
Using clopidogrel bisulfate: a new antiplatelet drug.
Topics: Arteriosclerosis; Clopidogrel; Drug Costs; Drug Interactions; Drug Monitoring; Humans; Patient Educa | 1999 |
[Creative mathematics with clopidogrel].
Topics: Advertising; Arteriosclerosis; Clopidogrel; Data Interpretation, Statistical; Drug Industry; Humans; | 1999 |
[Creative mathematics with clopidogrel; exaggeration of the preventive effect by the pharmaceutical company].
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Data I | 2000 |
[Clopidogrel].
Topics: Arteriosclerosis; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Strok | 2000 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Clinical and economic implications of atherosclerosis.
Topics: Arteriosclerosis; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor | 2000 |
Clinical and economic implications of atherosclerosis.
Topics: Arteriosclerosis; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor | 2000 |
Clopidogrel(TM): an alternative to acetylsalicylic acid and ticlopidine in antiplatelet therapy?
Topics: Arteriosclerosis; Canada; Cost-Benefit Analysis; Drug Evaluation; Heart Diseases; Humans; Ischemic A | 1999 |
A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events.
Topics: Arteriosclerosis; Cerebrovascular Disorders; Diarrhea; Female; Humans; Male; Neutropenia; Randomized | 1992 |
[Validation of an automatic quantification system in angiography. Research group studying ticlopidine in atherosclerosis of the lower leg].
Topics: Angiography; Arteriosclerosis; Femoral Artery; Humans; Iliac Artery; Ischemia; Leg; Models, Cardiova | 1989 |
[Erythrocyte filtration and membrane microviscosity during treatment with ticlopidine].
Topics: Aged; Arteriosclerosis; Blood Viscosity; Erythrocyte Deformability; Erythrocyte Membrane; Female; Hu | 1989 |
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Cl | 1985 |
In vivo effect of indobufen and ticlopidine hydrochloride on aortic endothelial integrity of normo- or hyper-cholesterolemic rats.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Endothelium; Hypercholesterolemia; Isoindoles; Male; Phe | 1987 |
Glucose and erythrocyte ATP: distinctive effects of dipyridamole and of ticlopidine.
Topics: Adenosine; Adenosine Triphosphate; Arteriosclerosis; Blood Glucose; Dipyridamole; Drug Therapy, Comb | 1987 |
[Problems of the elderly patient in anticoagulant and platelet-suppressant drug treatment].
Topics: Aged; Arteriosclerosis; Cholesterol; Female; Humans; Male; Platelet Aggregation; Thromboembolism; Ti | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |
[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Epoprost | 1985 |